Thousand Oaks, California-based human therapeutics developer Amgen's (NASDAQ: AMGN) supplemental Biologics License Application (sBLA) for Prolia (denosumab) for the treatment of patients with glucocorticoid-induced osteoporosis
(GIOP) has been accepted for review by the US Food and Drug Administration, the company said.
Risedronate is used in men and women for the prevention and treatment of osteoporosis and glucocorticoid-induced osteoporosis
A review of recent evidence focusing on glucocorticoid-induced osteoporosis
and osteoporosis associated with rheumatoid arthritis," Clinical Calcium, vol.
Teriparatide is approved to treat populations with osteoporosis at high risk for fracture, including postmenopausal women and men, and men and women with glucocorticoid-induced osteoporosis
Some of the men may have obvious secondary causes, such as glucocorticoid-induced osteoporosis
USPRwire, Thu Jun 05 2014] GlobalData's clinical trial report, "Glucocorticoid-Induced Osteoporosis
Global Clinical Trials Review, H1, 2014" provides data on the Glucocorticoid-Induced Osteoporosis
clinical trial scenario.
Alendronate sodium has also been subsequently approved for treatment of glucocorticoid-induced osteoporosis
, male osteoporosis, and in the elderly.
The bisphosphonates (BPs) are universally regarded as a first-line treatment for osteoporosis in postmenopausal and elderly women, in men, and in a number of secondary osteoporoses, including glucocorticoid-induced osteoporosis
Guide for the prevention and treatment of glucocorticoid-induced osteoporosis
of the Spanish Society of Internal Medicine.
They cover the epidemiology and genetics of postmenopausal osteoporosis, osteoporosis in men, the mechanisms of bone remodeling, fracture risk assessment, bone diseases and medications as secondary causes of osteoporosis, glucocorticoid-induced osteoporosis
, and treatment using hormone therapy, bisphosphonates, denosumab, parathyroid hormone, calcium and vitamin D, combination therapy, and emerging therapies, as well as monitoring therapy, persistence and compliance with medications to prevent fractures, and the approach to the patient.
Genistein aglycone reverses glucocorticoid-induced osteoporosis
and increases bone breaking strength in rats: a comparative study with alendronate.
It is used for the treatment of osteoporosis in men and women and for patients with glucocorticoid-induced osteoporosis
Since DHEA has an anabolic effect on bone, glucocorticoid-induced osteoporosis
might be due in part to the suppression of DHEA production.
Other uses include the treatment of glucocorticoid-induced osteoporosis
and Paget disease of bone in both sexes.
The incidence of glucocorticoid-induced osteoporosis
can be reduced by cutting the dose and/or duration of therapy, but not by adding a bisphosphonate.